TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: Evidence of a nonimmunological etiologyEVENS, Andrew M; KWAAN, Hau C; KAUFMAN, Dixon B et al.Transplantation. 2002, Vol 74, Num 6, pp 885-887, issn 0041-1337Article

Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphomaOLLBERDING, Nicholas J; EVENS, Andrew M; ASCHEBROOK-KILFOY, Briseis et al.British journal of haematology. 2013, Vol 163, Num 3, pp 352-356, issn 0007-1048, 5 p.Article

Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial- independent mechanismsBHALLA, Savita; GORDON, Leo I; EVENS, Andrew M et al.British journal of haematology. 2010, Vol 150, Num 3, pp 365-369, issn 0007-1048, 5 p.Article

Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyEVENS, Andrew M; SCHUMACKER, Paul T; HOLMGREN, Arne et al.British journal of haematology. 2008, Vol 141, Num 5, pp 676-680, issn 0007-1048, 5 p.Article

Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors : report from the Research on Adverse Drug Events and Reports (RADAR) projectBENNETT, Charles L; EVENS, Andrew M; BIERMAN, Philip J et al.British journal of haematology. 2006, Vol 135, Num 5, pp 642-652, issn 0007-1048, 11 p.Article

Chemotherapeutic Advancements in Peripheral T-Cell LymphomaREDDY, Nishitha M; EVENS, Andrew M.Seminars in hematology. 2014, Vol 51, Num 1, pp 17-24, issn 0037-1963, 8 p.Article

Motexafin Gadolinium Enhances p53-Mdm2 Interactions, Reducing p53 and Downstream Targets in Lymphoma Cell LinesSINGH, Amareshwar T. K; EVENS, Andrew M; PRACHAND, Sheila N et al.Anticancer research. 2010, Vol 30, Num 4, pp 1131-1136, issn 0250-7005, 6 p.Article

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraHOSEIN, Peter J; MARAGULIA, Jocelyn C; ISLAM, Nahida et al.British journal of haematology. 2014, Vol 165, Num 3, pp 358-363, issn 0007-1048, 6 p.Article

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496EVENS, Andrew M; FANGXIN HONG; STIFF, Patrick J et al.British journal of haematology. 2013, Vol 161, Num 1, pp 76-86, issn 0007-1048, 11 p.Article

Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter AnalysisEVENS, Andrew M; ADVANI, Ranjana; KROLL-DESROSIERS, Aimee et al.Journal of clinical oncology. 2013, Vol 31, Num 32, pp 4132-4139, issn 0732-183X, 8 p.Conference Paper

Clinical, Morphologic, Immunophenotypic, and Molecular Cytogenetic Assessment of CD4-/CD8- γδ T-Cell Large Granular Lymphocytic LeukemiaCHEN, Yi-Hua; CHADBURN, Amy; EVENS, Andrew M et al.American journal of clinical pathology. 2011, Vol 136, Num 2, pp 289-299, issn 0002-9173, 11 p.Article

Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculataSHUO YANG; EVENS, Andrew M; PRACHAND, Sheila et al.Clinical cancer research (Print). 2010, Vol 16, Num 19, pp 4755-4768, issn 1078-0432, 14 p.Article

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cellsEVENS, Andrew M; LECANE, Philip; MAGDA, Darren et al.Blood. 2005, Vol 105, Num 3, pp 1265-1273, issn 0006-4971, 9 p.Article

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II studyEVENS, Andrew M; SMITH, Mitchell R; LOSSOS, Izidore S et al.British journal of haematology. 2014, Vol 166, Num 4, pp 514-520, issn 0007-1048, 7 p.Article

Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)CERNY, Jan; HONGBO YU; KROLL-DESROSIERS, Aimee et al.British journal of haematology. 2013, Vol 160, Num 2, pp 262-266, issn 0007-1048, 5 p.Article

CD23+ Mantle Cell Lymphoma : A Clinical Pathologic Entity Associated With Superior Outcome Compared With CD23-DiseaseKELEMEN, Katalin; PETERSON, Loann C; GORDON, Leo I et al.American journal of clinical pathology. 2008, Vol 130, Num 2, pp 166-177, issn 0002-9173, 12 p.Article

Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependentEVENS, Andrew M; PRACHAND, Sheila; BO SHI et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1481-1491, issn 1078-0432, 11 p.Article

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaGENTZLER, Ryan D; EVENS, Andrew M; SINGHAL, Seema et al.British journal of haematology. 2014, Vol 165, Num 6, pp 793-800, issn 0007-1048, 8 p.Article

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasEVENS, Andrew M; ROSEN, Steven T; HELENOWSKI, Irene et al.British journal of haematology. 2013, Vol 163, Num 1, pp 55-61, issn 0007-1048, 7 p.Article

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaBHALLA, Savita; EVENS, Andrew M; DAI, Bojie et al.Blood. 2011, Vol 118, Num 4, pp 1052-1061, issn 0006-4971, 10 p.Article

Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOPEVENS, Andrew M; SEHN, Laurie H; GASCOYNE, Randy D et al.Journal of clinical oncology. 2010, Vol 28, Num 6, pp 1017-1024, issn 0732-183X, 8 p.Article

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-_KB Mechanisms and Is Synergistic with Bortezomib in Lymphoma CellsBHALLA, Savita; BALASUBRAMANIAN, Sriram; DAVID, Kevin et al.Clinical cancer research (Print). 2009, Vol 15, Num 10, pp 3354-3365, issn 1078-0432, 12 p.Article

Anaplastic Large-Cell Lymphoma in Women With Breast Implants. CommentaryDE JONG, Daphne; VASMEL, Wies L. E; DE BOER, Jan Paul et al.JAMA, the journal of the American Medical Association. 2008, Vol 300, Num 17, issn 0098-7484, 2030-2035, 2059-2061 [9 p.]Article

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisEVENS, Andrew M; CILLEY, Jeffrey; TALLMAN, Martin S et al.British journal of haematology. 2007, Vol 137, Num 6, pp 545-552, issn 0007-1048, 8 p.Article